Loading...
Loading...
Contributors:
Dataset URI:
10.3389/fcell.2026.1967923.s001BackgroundThe high incidence of distant metastasis in triple-negative breast cancer (TNBC) remains the principal driver of disease-related mortality, highlighting an urgent clinical need for novel therapeutics to restrict tumor progression and dissemination.MethodsWe investigated the anti-tumor potential and underlying molecular mechanisms of MHO7 (6-epi-ophiobolin G), a structurally unique sesterterpenoid derived from a marine fungus, using MDA-MB-231 cells in vitro and a subcutaneous xenograft model in vivo. Transcriptomic profiling and biochemical analyses were performed to elucidate the underlying signaling alterations.ResultsBoth in vitro and in vivo evaluations demonstrated that MHO7 profoundly curtails MDA-MB-231 cell migration and invasion, strengthens adherens junctions, and exhibits robust primary tumor growth inhibition without inducing overt systemic toxicity in preclinical mouse models. Mechanistically, transcriptomic profiling coupled with biochemical analyses revealed that MHO7 exerts inhibitory effects on cell migration and invasion primarily by attenuating the Focal Adhesion Kinase (FAK) signaling pathway. Specifically, MHO7 treatment remarkably suppressed the autophosphorylation of FAK (Y397) and the subsequent recruitment of p-Src (Y419). This pathway suppression consequently altered cytoskeletal architecture, attenuated the downstream PI3K/AKT signaling cascade, and curtailed tumor angiogenesis. Furthermore, we identified a dual inhibitory mechanism wherein MHO7 successfully dismantled the oncogenic crosstalk between FAK and the canonical Wnt/β-catenin pathway by significantly downregulating nuclear β-catenin accumulation.ConclusionMHO7 exerts tumor-suppressive and anti-migratory effects in TNBC primarily by attenuating FAK signaling and its downstream pathways, supporting its potential as a promising therapeutic candidate for highly aggressive TNBC.
Keyword(s):
Cell Biology; cell migration and invasion; FAK signaling pathway; MHO7; sesterterpenoid.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)